Revenue
$0
Net Income
-$377.9M
▼ 53.5% YoY
EPS
$-3.29
▼ 33.2% YoY
Cash
$323.5M
▲ 81.9% YoY
FY 2025 · As of 2025-12-31
Last 90 days
| Insider | Type | Date | Shares | Price | Value | |
|---|---|---|---|---|---|---|
Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sell | Feb 23, 2026 | 7.4K | $46.94 | $349K | Form 4 ↗ |
Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sell | Feb 23, 2026 | 857 | $47.86 | $41K | Form 4 ↗ |
Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sell | Feb 23, 2026 | 200 | $48.48 | $10K | Form 4 ↗ |
Marantz Jing L. CHIEF MEDICAL OFFICER | Sell | Feb 17, 2026 | 4.2K | $46.53 | $193K | Form 4 ↗ |
Ho Junlin GENERAL COUNSEL | Sell | Feb 17, 2026 | 9.6K | $46.53 | $446K | Form 4 ↗ |
Parlavecchio Caryn CHRO | Sell | Feb 17, 2026 | 9.0K | $46.53 | $420K | Form 4 ↗ |
Qatanani Mo CHIEF SCIENTIFIC OFFICER | Sell | Feb 17, 2026 | 8.0K | $46.53 | $372K | Form 4 ↗ |
Vaishnaw Akshay President of R&D | Grant | Feb 9, 2026 | 47.0K | $0.00 | $0 | Form 4 ↗ |
Sinha Vikas Chief Financial Officer | Grant | Feb 9, 2026 | 47.0K | $0.00 | $0 | Form 4 ↗ |
Qatanani Mo Chief Scientific Officer | Grant | Feb 9, 2026 | 29.3K | $0.00 | $0 | Form 4 ↗ |
Parlavecchio Caryn Chief Human Resources Officer | Grant | Feb 9, 2026 | 29.3K | $0.00 | $0 | Form 4 ↗ |
Marantz Jing L. Chief Medical Officer | Grant | Feb 9, 2026 | 34.5K | $0.00 | $0 | Form 4 ↗ |
Ho Junlin General Counsel | Grant | Feb 9, 2026 | 36.6K | $0.00 | $0 | Form 4 ↗ |
Hallal David Chief Executive Officer | Grant | Feb 9, 2026 | 128.0K | $0.00 | $0 | Form 4 ↗ |